Key statistics
On Friday, Alvotech SA (ALVO:NMQ) closed at 11.12, 33.98% above the 52 week low of 8.30 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.19 |
---|---|
High | 11.20 |
Low | 10.95 |
Bid | 4.45 |
Offer | 15.00 |
Previous close | 11.18 |
Average volume | 77.35k |
---|---|
Shares outstanding | 301.48m |
Free float | 107.18m |
P/E (TTM) | -- |
Market cap | 3.35bn USD |
EPS (TTM) | -2.65 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:15 BST.
More ▼
- Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Alvotech tekur þátt í árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanley
- Alvotech skilar mettekjum og metframlegð á öðrum ársfjórðungi og á fyrri helmingi ársins
- Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
- Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT06, fyrirhugaða líftæknilyfjahliðstæðu við Eylea
- Alvotech mun birta uppgjör fyrri árshelmings 2024 fimmtudaginn 15. ágúst nk. og streyma uppgjörsfundi föstudaginn 16. ágúst nk. kl. 12:00 að íslenskum tíma
- Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
- STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu
- STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
More ▼